"label" trang 8 - tải miễn phí từ tailieuXANH
Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
12    62    0
Phase II, multi-center, open-label, singlearm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): Rationale and design of the ESMMO trial

Phase II, multi-center, open-label, singlearm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): Rationale and design of the ESMMO trial
10    59    0
Non-destructive, label free identification of cell cycle phase in cancer cells by multispectral microscopy of autofluorescence

Non-destructive, label free identification of cell cycle phase in cancer cells by multispectral microscopy of autofluorescence
11    76    0
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study
7    52    0
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
5    57    0
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: Protocol for an open-label, non-randomised, Phase 2 study

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: Protocol for an open-label, non-randomised, Phase 2 study
6    48    0
Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, singlearm phase II study

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, singlearm phase II study
8    62    0
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, noncomparative, randomized, multicenter phase II study

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, noncomparative, randomized, multicenter phase II study
7    57    0
Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: A multicenter, open-label randomized controlled study

Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: A multicenter, open-label randomized controlled study
10    48    0
ACRNaCT trial protocol: Efficacy of adjuvant chemotherapy in patients with clinical T3b/ T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: A pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial

ACRNaCT trial protocol: Efficacy of adjuvant chemotherapy in patients with clinical T3b/ T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: A pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial
7    91    0
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): An open label, non-comparative, phase II trial

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): An open label, non-comparative, phase II trial
10    54    0
Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: A multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: A multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators
11    84    0
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
11    89    0
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
11    69    0
Selection of opioids for cancer-related pain using a biomarker: A randomized, multiinstitutional, open-label trial (RELIEF study)

Selection of opioids for cancer-related pain using a biomarker: A randomized, multiinstitutional, open-label trial (RELIEF study)
6    91    0
Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
8    103    0
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial
7    74    0
Apatinib for advanced sarcoma: Results from multiple institutions’ off-label use in China

Apatinib for advanced sarcoma: Results from multiple institutions’ off-label use in China
10    58    0
Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study

Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study
7    73    0
A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment

A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment
9    66    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.